BridgeBio Pharma, Inc.
BBIO
$32.19
-$0.82-2.48%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 221.90M | 217.77M | 219.12M | 218.60M | 9.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 221.90M | 217.77M | 219.12M | 218.60M | 9.30M |
| Cost of Revenue | 3.88M | 2.39M | 2.39M | 2.39M | 2.45M |
| Gross Profit | 218.02M | 215.37M | 216.73M | 216.20M | 6.86M |
| SG&A Expenses | 288.93M | 241.73M | 208.69M | 185.29M | 150.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 799.27M | 750.46M | 722.11M | 691.50M | 608.75M |
| Operating Income | -577.37M | -532.70M | -502.99M | -472.91M | -599.44M |
| Income Before Tax | -542.19M | -446.29M | -461.52M | -546.68M | -653.25M |
| Income Tax Expenses | 1.15M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -543.35 | -446.29 | -461.52 | -546.68 | -653.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 7.59M | 7.43M | 7.70M | 8.42M | 10.05M |
| Net Income | -535.76M | -438.86M | -453.82M | -538.26M | -643.20M |
| EBIT | -577.37M | -532.70M | -502.99M | -472.91M | -599.44M |
| EBITDA | -571.29M | -526.40M | -496.59M | -466.45M | -592.95M |
| EPS Basic | -2.85 | -2.41 | -2.64 | -3.23 | -3.95 |
| Normalized Basic EPS | -2.24 | -2.06 | -2.02 | -1.97 | -2.47 |
| EPS Diluted | -2.85 | -2.41 | -2.64 | -3.23 | -3.95 |
| Normalized Diluted EPS | -2.24 | -2.06 | -2.02 | -1.97 | -2.47 |
| Average Basic Shares Outstanding | 744.24M | 729.26M | 704.06M | 677.01M | 650.95M |
| Average Diluted Shares Outstanding | 744.24M | 729.26M | 704.06M | 677.01M | 650.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
